June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Impact of Ranibizumab on Patient-Reported Visual Functioning in Myopic Choroidal Neovascularization: 3- and 6-Month Results
Author Affiliations & Notes
  • Kyoko Ohno-Matsui
    Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University Hospital, Tokyo, Japan
  • Nikolle Tan
    Department of Ophthalmology, Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore, Singapore
  • Tien Wong
    Department of Ophthalmology, National University of Singapore, Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore
  • Tatsuro Ishibashi
    Department of Ophthalmology, Kyushu University Hospital, Fukuoka, Japan
  • Jennifer Petrillo
    Novartis Pharmaceuticals Corporation, East Hanover, NJ
  • Neil Bressler
    Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD
  • Claudia Leteneux
    Novartis AG, Basel, Switzerland
  • Footnotes
    Commercial Relationships Kyoko Ohno-Matsui, None; Nikolle Tan, Novartis (C), Novartis (R), Novartis (S), Bayer (C), Bayer (R), Bayer (S), Allergan (R), Allergan (S); Tien Wong, Allergan (C), Bayer (C), Novartis (C), Pfizer (C), GSK (F), Roche (F); Tatsuro Ishibashi, None; Jennifer Petrillo, Novartis Pharmaceuticals (E); Neil Bressler, Abbott Medical Optics, inc (F), Alimera Sciences (F), Allergan (F), Bausch &Lomb, Inc (F), Bayer (F), Carl Zeiss Meditec, Inc (F), ForSight Labs, LLC (F), Genentech, Inc (F), Genzyme Corporation (F), Lumenis, Inc (F), Notal VIsion (F), Novartis Pharma AG (F), Pfizer, Inc (F), Regeneron Pharmaceuticals, Inc (F), Roche (F), Thrombogencis (F); Claudia Leteneux, Novartis Pharma AG (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 1245. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Kyoko Ohno-Matsui, Nikolle Tan, Tien Wong, Tatsuro Ishibashi, Jennifer Petrillo, Neil Bressler, Claudia Leteneux; Impact of Ranibizumab on Patient-Reported Visual Functioning in Myopic Choroidal Neovascularization: 3- and 6-Month Results. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1245.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To examine the effects of 0.5 mg ranibizumab given for 6 months on visual functioning among patients with myopic choroidal neovascularization (CNV).

Methods: In a phase 3, multi-country study, patients were randomized to: at least two monthly ranibizumab injections with subsequent retreatment based on visual acuity criteria (stabilization group, n = 106); at least one ranibizumab injection with subsequent retreatment based on optical coherent tomography or fluorescein angiography features (disease activity group, n = 116); or verteporfin photodynamic therapy (vPDT, n = 55). From month 3, patients assigned to vPDT could receive ranibizumab. The National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) was administered in the local language at baseline, 3 months and 6 months to measure patient-reported visual functioning. Initial results from an exploratory analysis (including descriptive p-values) are reported using last observation carried forward analysis.

Results: The mean baseline NEI VFQ-25 composite score was 69.3, 71.0 and 71.9 in the stabilization, disease activity and vPDT groups, respectively. At month 3, the mean increase from baseline in NEI VFQ-25 composite score was greater in the stabilization (5.3 points, p < 0.05) and disease activity (4.3 points, p < 0.05) groups than in the vPDT group (0.3 points). At month 6, the mean increase from baseline in the composite score was 6.3 and 5.1 points in each ranibizumab group, respectively. In the subscales of near activities and mental health, some greater improvements were observed with ranibizumab (both groups) than with vPDT. At month 3, the mean increase from baseline in near activities score was 11.5 points (p < 0.01) and 5.3 points (p = 0.138) in the stabilization and disease activity groups compared with 0.9 points in the vPDT group. Mental health scores increased by 7.4 points (p < 0.05) and 4.9 points (p < 0.05) and decreased by 1.8 points in these groups, respectively. At month 6, the increase from baseline was sustained at 10.0 and 6.5 points for near activities and 10.3 and 8.9 points for mental health in the stabilization and disease activity groups, respectively.

Conclusions: The improvement in patient-reported visual functioning in patients with myopic CNV was greater for some NEI VFQ-25 subscales at 3 months with ranibizumab than with vPDT. These improvements were sustained at 6 months.

Keywords: 453 choroid: neovascularization • 605 myopia • 754 visual acuity  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.